Calcium channel blockers versus other classes of drugs for hypertension - Wikidata - awgldk - TriplyDB

Calcium channel blockers versus other classes of drugs for hypertension

Calcium channel blockers versus other classes of drugs for hypertension

http://www.wikidata.org/entity/Q24236584

about

Blood pressure lowering efficacy of beta-1 selective beta blockers for primary hypertension Antihypertensive pharmacotherapy for prevention of sudden cardiac death in hypertensive individuals First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension Antihypertensive pharmacotherapy for prevention of sudden cardiac death in hypertensive individuals Blood pressure lowering efficacy of dual alpha and beta blockers for primary hypertension First-line beta-blockers versus other anti-hypertensive medications for chronic type B aortic dissections Beta-blockers for hypertension Time course for blood pressure lowering of dihydropyridine calcium channel blockers Beta-blockers for hypertension Drug Interactions in Parkinson's Disease: Safety of Pharmacotherapy for Arterial Hypertension Beta-blockers for hypertension.First-line combination therapy versus first-line monotherapy for primary hypertension.Choice of generic antihypertensive drugs for the primary prevention of cardiovascular disease--a cost-effectiveness analysis Management of hypertension and multiple risk factors to enhance cardiovascular health - a feasibility study in Singapore polyclinics.Stroke prevention: managing modifiable risk factors.1,4-dihydropyridines: the multiple personalities of a blockbuster drug family.Blood pressure targets for hypertension in older adults.Negative inotropism of terpenes on guinea pig left atrium: structure-activity relationships.Tocotrienol is a cardioprotective agent against ageing-associated cardiovascular disease and its associated morbidities.A Genome-Wide Association Study of Idiopathic Dilated Cardiomyopathy in African Americans.Management of hypertension and multiple risk factors to enhance cardiovascular health in Singapore: The SingHypertension cluster randomized trial.

P2860

Q24186037-99BFC5E8-FCBE-4F37-BC7F-DA8BD2FC28BF Q24186039-BBC86D02-1719-4BC9-9560-144A7E707D47 Q24186647-2520B379-C383-4D8D-84C6-A52DDD832B0D Q24187556-16760077-4D59-41D5-ABE8-56D51A79474E Q24187752-F1738740-418B-4F30-AB78-9C79A5298F76 Q24200438-014BFE52-E1F6-46B0-B823-D02F678B3D35 Q24201511-A64D2097-3C8D-4252-A1AD-AAA0BE7624E2 Q24201835-470E0FE5-7817-4081-A907-92F815E1E058 Q24202812-E619B98D-3F18-4DD7-8B0C-0B83544E2D55 Q28085554-827850E1-5C3E-443D-A91D-6CBEE9EFE56D Q30238911-24755195-C62A-4139-8331-1AF371528AE8 Q30239037-8D2B2AC4-F64D-432A-AB05-7F856AC5AADF Q34219946-742BA3E6-02A8-4A15-977A-EC631CFB4943 Q36071553-253116C9-08BF-4883-9D87-B9994F15AB8C Q36418118-7D637BEA-7651-4251-BDB1-D7889938F688 Q38125687-31FA999B-BBAA-4D44-8B1A-95EB0DB417F9 Q38634623-97916FB2-0D6F-4414-8C6B-F35E4B8FA318 Q38667921-D4BF5CD6-0500-4740-8383-44049FA5C647 Q48129928-1958F43A-74C3-43EA-B88A-F46368E8FACF Q52679111-489A5E85-C110-4043-9C13-E661CD35DA4A Q54965266-95037724-F53F-40B2-887E-1D446C501E1A

P2860

Calcium channel blockers versus other classes of drugs for hypertension

http://www.wikidata.org/entity/Q24236584

description

2010 nî lūn-bûn

@nan

2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Calcium channel blockers versus other classes of drugs for hypertension

@ast

Calcium channel blockers versus other classes of drugs for hypertension

@en

Calcium channel blockers versus other classes of drugs for hypertension

@en-gb

Calcium channel blockers versus other classes of drugs for hypertension

@nl

type

label

Calcium channel blockers versus other classes of drugs for hypertension

@ast

Calcium channel blockers versus other classes of drugs for hypertension

@en

Calcium channel blockers versus other classes of drugs for hypertension

@en-gb

Calcium channel blockers versus other classes of drugs for hypertension

@nl

prefLabel

Calcium channel blockers versus other classes of drugs for hypertension

@ast

Calcium channel blockers versus other classes of drugs for hypertension

@en

Calcium channel blockers versus other classes of drugs for hypertension

@en-gb

Calcium channel blockers versus other classes of drugs for hypertension

@nl

P1433

Q24236584-05246674-B299-43A0-9309-BE14F237CF2B

P1476

Q24236584-12BF95C8-6F41-4829-BA2A-346AC6EEEA29

P2093

Q24236584-175D02C5-D2ED-400C-B234-E80823EAF597

Q24236584-22A91AB9-F39E-486A-8278-5BE5B63B74A1

Q24236584-24B1DEEC-0439-4066-A77D-1C237FCDBCD6

Q24236584-5F2E50AF-E88C-43D8-A0F9-CF35B5494EBD

Q24236584-8EE6EDC3-9660-4F4C-92B3-6F980FEA4164

Q24236584-CDB7B21C-0244-4F44-B944-7EA3057145CC

Q24236584-D87E9065-9271-4F31-8E30-D6228A928991

Q24236584-E3EB430E-EF3E-416B-92BD-5D33F0536C89

Q24236584-F8BE9F71-CA4C-4F7A-97ED-FD9E87CED5EE

P2860

Q24236584-00220BE8-B597-4BD5-97CD-699D981497BB

Q24236584-05C3A6CF-016A-4D5B-99CC-285FA7B401DB

Q24236584-0619A3CC-7D76-48A8-9BA9-05FC4A4EB2DD

Q24236584-10B28782-4E47-4ECA-8D7E-3745685F15C9

Q24236584-1353EF4C-00C4-4FB8-84F9-1C8C156C1707

Q24236584-1439AFA3-2275-4112-8216-7457805EC3F2

Q24236584-1985D3F2-06EF-48E1-8E5C-401213FE85CE

Q24236584-1A622CA9-745D-4C85-90E4-E92BDB7EE08F

Q24236584-1D5A9A5E-399E-4945-A246-9D1E2B016672

Q24236584-20F115FA-B73E-45C5-B704-6F3B16240BCD

P31

Q24236584-9346a7ca-7889-4cb6-83cf-53d4f1ae6efa

Q24236584-E825308B-429F-4F30-BCB5-33010F691513

P3181

Q24236584-B8BC070A-7136-420E-8193-BE731C4E9691

P356

Q24236584-2DAA9710-0C31-4619-BF35-BCE896067574

P577

Q24236584-6E540E40-0D94-48E8-A0E3-3F25D07EEF7D

P698

Q24236584-84BAD6F4-E6C1-4496-957B-96461CA8FCA6

P921

Q24236584-1BBFAA97-8AA4-42E7-98B3-684000CAF455

P3181

P356

14651858.CD003654.PUB4

P1433

Cochrane Database of Systematic Reviews

P1476

Calcium channel blockers versus other classes of drugs for hypertension

@en

P2093

Cairong Zhu

http://www.w3.org/2001/XMLSchema#string

Jian Guo

http://www.w3.org/2001/XMLSchema#string

Jie Yang

http://www.w3.org/2001/XMLSchema#string

Li He

http://www.w3.org/2001/XMLSchema#string

Mi Yang

http://www.w3.org/2001/XMLSchema#string

Muke Zhou

http://www.w3.org/2001/XMLSchema#string

Ning Chen

http://www.w3.org/2001/XMLSchema#string

Xue Yang

http://www.w3.org/2001/XMLSchema#string

Yucai Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

First-line drugs for hypertension

Beta-blockers for hypertension

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

Selected major risk factors and global and regional burden of disease

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT).

Post-randomisation exclusions: the intention to treat principle and excluding patients from analysis.

P31

scholarly article

P3181

156732

http://www.w3.org/2001/XMLSchema#string

P356

10.1002/14651858.CD003654.PUB4

http://www.w3.org/2001/XMLSchema#string

P577

2010-08-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20687074

http://www.w3.org/2001/XMLSchema#string

P921

arterial hypertension